|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions显示文摘About 75% of all breast cancers are estrogen receptor(ER)-positive. They generally have a more favorable clinical behavior, prognosis, and pattern of recurrence, and endocrine therapy forms the backbone of treatment. Anti-estrogens(such as tamoxifen and fulvestrant) and aromatase inhibitors(such as anastrozole, letrozole, and exemestane) can effectively control the disease and induce tumor responses in a large proportion of patients. However, the majority of patients progress during endocrine therapy(acquired resistance) and a proportion of patients may fail to respond to initial therapy(de novo resistance). Endocrine resistance is therefore of clinical concern and there is great interest in strategies that delay or circumvent it. A deeper knowledge of the molecular mechanisms that drive endocrine resistance has recently led to development of new strategies that have the promise to effectivelyovercome it. Many resistance mechanisms have been described, and the crosstalk between ER and growth factor receptor signaling pathways seems to represent one of the most relevant. Compounds that are able to inhibit key elements of these pathways and restore endocrine sensitivity have been studied and more are currently under development. The aim of this review is to summarize the molecular pathophysiology of endocrine resistance in breast cancer and its impact on current clinical management. | Andrea Milani Elena Geuna Gloria Mittica Giorgio Valabrega | 2014 | World Journal of Clinical Oncology2014，5，5： | 18 |
| 2 | Helicobacter pylori eradication: Sequential therapy and Lactobacillus reuteri supplementation显示文摘AIM:To evaluate the role of sequential therapy and Lactobacillus reuteri (L. reuteri ) supplementation, in the eradication treatment of Helicobacter pylori (H. pylori ). METHODS:H. pylori infection was diagnosed in 90 adult dyspeptic patients. Patients were excluded if previously treated for H. pylori infection or if they were taking a proton pump inhibitor (PPI), H2-receptor antagonist or antibiotics. Patients were assigned to receive one of the following therapies:(1) 7-d triple therapy (PPI plus clarithromycin and amoxicillin or metronidazole) plus L. reuteri supplementation dur- ing antibiotic treatment; (2) 7-d triple therapy plus L. reuteri supplementation after antibiotic treatment; (3) sequential regimen (5-d PPI plus amoxicillin therapy followed by a 5-d PPI, clarithromycin and tinidazole) plus L. reuteri supplementation during antibiotic treatment; and (4) sequential regimen plus L. reuteri supplementation after antibiotic treatment. Successful eradication therapy was defined as a negative urea breath test at least 4 wk following treatment. RESULTS:Ninety adult dyspeptic patients were en- rolled, and 83 (30 male, 53 female; mean age 57 ± 13 years) completed the study. Nineteen patients were administered a 7-d triple treatment:11 with L. reuteri supplementation during and 8 after therapy. Sixty-four patients were administered a sequential regimen:32 with L. reuteri supplementation during and 32 after therapy. The eradication rate was significantly higher in the sequential group compared with the 7-d triple regimen (88% vs 63%, P = 0.01). No difference was found between two types of PPI. No difference in erad- ication rates was observed between patients submitted to L. reuteri supplementation during or after antibiotic treatment. Compliance with therapy was excellent in all patients. No difference in adverse effects was observed between the different antibiotic treatments and between patients submitted to L. reuteri supplementation during and after antibiotic treatment. There was a low incidence of adverse effects in all groups of patients with sequential therapy, probably due to the presence of the L. reuteri supplementation. CONCLUSION:The sequential treatment regimen achieved a significantly higher eradication rate of H. pylori compared with standard 7-d regimen. L. reuteri supplementation could reduce the frequency and the intensity of antibiotic-associated side-effects. | Cesare Efrati Giorgia Nicolini Claudio Cannaviello Nicole Piazza O'Sed Stefano Valabrega | 2012 | World Journal of Gastroenterology2012，18，43： | 4 |
| 3 | Trastuzum ab:mechanism of action, resistance and Future perspectives in Her-2 overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 4 | Lapatinib: a dual inhibitor of EGFR and HER-2 tyrosine kinase activ- ity 显示文摘 | Montemurro F Valabrega G Aglietta M | 2007 | Expert Opin Biol Ther2007，7，2： | 1 |
| 5 | HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 显示文摘 | Valabrega G Capellero S Cavalloni G | 2011 | Breast Cancer Res Treat2011，130，1： | 1 |
| 6 | Trastuzumab:mechanism of action,resistance and future perspectives in HER-2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 7 | Trastuzumab:mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，： | 1 |
| 8 | Trastuzum-ab: mechanism of action, resistance and future perspectives inHER2-overexpressing breast cancer 显示文摘 | VALABREGA G MONTEMURRO F AGUETTA M | 2007 | Ann Oncol2007，18，6： | 1 |
| 9 | Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 10 | Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study 显示文摘 | TRIMBOLI P GIOVANELLA L VALABREGA S | 2014 | Journal of Experimental & Clinical Cancer Research2014，33，1： | 1 |
| 11 | Trastuzumab-based combination therapy for breast-cancer显示文摘 | Montemurro F Valabrega G Aglietta M | 2004 | Expert Opin Pharmatother2004，5，： | 1 |
| 12 | Trastuzumab:mechanism of action,resistance and future perspectives in HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 13 | Trastuzumab treatment in breast cancer显示文摘 | Montemurro F Valabrega G Aglietta M | 2006 | N Engl J Med2006，354，： | 1 |
| 14 | Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience显示文摘BACKGROUND Gynecological malignancies represent a major cause of death in women and are often treated with platinum-based regimens.Patients undergoing chemotherapy suffer from alterations in nutritional status which may worsen gastrointestinal(GI)toxicities,quality of life and affect the overall prognosis.Indeed,assuring a good nutritional status and limiting toxicities during treatment are still major goals for clinicians.AIM To assess the role of Mediterranean Diet(MD)in reducing GI toxicities in patients with gynecological cancers treated with platinum-based regimens.METHODS We conducted an observational study on 22 patients with gynecological tumors treated with a platinum-based chemotherapy at Candiolo Cancer Institute FPO/IRCCS between January 2018 and June 2018.The food and frequency(FFQ)and the Patient-Reported Outcomes Common Terminology Criteria For Adverse Events(PRO-CTCAE)questionnaires were administered at baseline and at every Day 1 of each cycle.To evaluate the differences in GI toxicities the study population was divided in two groups according to the currently validated Mediterranean Diet Serving Score(MDSS)at baseline.RESULTS Patients with high MDSS reported a trend toward lower GI toxicities according to PRO-CTCAE at each timepoint(first evaluation:P=0.7;second:P=0.52;third:P=0.01).In particular,difference in nausea frequency and gravity(P<0.001),stomach pain frequency and gravity(P=0.01 and P=0.02),abdomen bloating frequency and gravity(P=0.02 and P=0.03),and interference with daily activities(P=0.02)were highly statistically significant at the end of treatment.More than 60%of patients changed their food habits during chemotherapy mainly because of GI toxicities.A higher reduction of food intake,both in terms of caloric(P=0.29)and of single nutrients emerged in the group experiencing higher toxicity.CONCLUSION Our results show that adherence to MD possibly reduces GI toxicity and prevents nutritional status impairment during chemotherapy treatment.Bigger studies are needed to confirm our results. | Eleonora Ghisoni Valentina Casalone Gaia Giannone Gloria Mittica Valentina Tuninetti Giorgio Valabrega | 2019 | World Journal of Clinical Oncology2019，10，12： | 1 |
| 15 | ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells 显示文摘 | Valabrega G Fagioli F Corso S | 2003 | Br J Cancer2003，88，3： | 1 |
| 16 | Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Arm Oncol2007，18，6： | 1 |
| 17 | Lapatinib-a dual inhibitor of EGFR and HER2 tyrosine kinase activity显示文摘 | Montemurro F Valabrega G Aglietta M | 2007 | Expert Opin Biol Ther2007，7，2： | 1 |
| 18 | ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells 显示文摘 | Valabrega G Fagioli F Corso S | 2003 | Br J Cancer2003，88，3： | 1 |
| 19 | Trastuzumab-based com-bination therapy for breast cancer显示文摘 | Montemurro F Valabrega G Aglietta M | 2004 | Expert Opin Pharmacoth-er2004，5，： | 1 |
| 20 | Trastuzumab: mecha nism of action, resistance and future perspectives in HER2-over expressing breast cancer显示文摘 | Valabrega G Aglietta M | 2007 | An nals of ()ncology2007，18，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员